These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29899212)

  • 1. Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.
    Flanagan S; Minassian SL; Prokocimer P
    J Clin Med; 2018 Jun; 7(6):. PubMed ID: 29899212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
    Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects.
    Chen R; Shen K; Chang X; Tanaka T; Li L; Hu P
    Clin Ther; 2016 Aug; 38(8):1869-79. PubMed ID: 27461846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
    Flanagan SD; Bien PA; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Mar; 34(3):240-50. PubMed ID: 23926058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
    Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via
    Stainton SM; Monogue ML; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
    Tran JQ; Zhang P; Walker S; Ghosh A; Syto M; Wang X; Harris S; Palmisano M
    Adv Ther; 2020 Dec; 37(12):4944-4958. PubMed ID: 33025342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
    Li D; Sabato PE; Guiastrennec B; Ouerdani A; Feng HP; Duval V; De Anda CS; Sears PS; Chou MZ; Hardalo C; Broyde N; Rizk ML
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0089521. PubMed ID: 34516243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.
    Hall RG; Michaels HN
    Infect Drug Resist; 2015; 8():75-82. PubMed ID: 25960671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
    Flanagan SD; Minassian SL; Prokocimer P
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):788-794. PubMed ID: 29319932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.
    Flanagan S; Litwin J; Fang E; Prokocimer P
    Int J Antimicrob Agents; 2016 Jul; 48(1):33-40. PubMed ID: 27342387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.
    Pai MP
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4585-9. PubMed ID: 27185808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.